Literature DB >> 28377354

[Inhibitory effect of apatinib on HCT-116 cells and its mechanism].

Liang Yin1, Jin Wang, Feng-Chang Huang, Yun-Fei Zhang, Ning Xu, Zheng-Qi Wen, Wen-Liang Li, Jian Dong.   

Abstract

OBJECTIVE: To investigate the inhibitory effects of apatinib on colorectal carcinoma HCT-116 cells in vitro and the signaling pathways involved.
METHODS: The cytotoxicity of different concentrations (0, 0.5, 1, 1.5, and 2 µmol/L) of apatinib in HCT-116 cells was assessed by MTT assay, using capecitabine as the positive control. The apoptosis rate of apatinib-treated HCT-116 cells was detected using flow cytometry, and the expressions of Bcl-2, Bax, and caspase-3 were determined with quantitative real-time PCR and Western blotting. The effect of apatinib on the expressions of Akt, pAkt, Erk1/2 and pErk1/2 in HCT-116 cells was evaluated using Western blotting.
RESULTS: Apatinib significantly inhibited the proliferation of HCT-116 cells in a concentration-dependent manner with an IC50 value of 1.335 µmol/L. Flow cytometric analysis showed that apatinib significantly increased the apoptotic rate of HCT-116 cells dose-dependently. Apatinib induced the expression of the pro-apoptotic genes Bax and caspase-3 at both the mRNA and protein levels while inhibited the expression of the anti- apoptotic gene Bcl-2. The expressions of p-Akt and p-Erk1/2 were decreased in HCT-116 cells after apatinib treatment, but the total protein levels did not undergo obvious changes.
CONCLUSION: Apatinib inhibits the proliferation and induces apoptosis of HCT-116 cells by suppressing the phosphorylation of Erk1/2 and Akt in the MAPK/Erk and PI3K/Akt signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28377354      PMCID: PMC6780439     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  16 in total

Review 1.  [Tyrosine kinase receptor-mediated signal transduction and cancer treatment].

Authors:  Xiao-feng Zhu; Zong-chao Liu; Yi-xin Zeng
Journal:  Yao Xue Xue Bao       Date:  2002-03

2.  Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2.

Authors:  Chad E Darling; Rong Jiang; Michelle Maynard; Peter Whittaker; Jakob Vinten-Johansen; Karin Przyklenk
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-06-03       Impact factor: 4.733

3.  Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation.

Authors:  Xi-Ming Yang; Sebastian Philipp; James M Downey; Michael V Cohen
Journal:  Basic Res Cardiol       Date:  2004-11-25       Impact factor: 17.165

4.  YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.

Authors:  Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin Li; Liguang Lou
Journal:  Cancer Sci       Date:  2011-05-09       Impact factor: 6.716

5.  Local recurrence of colorectal cancer: the problem, mechanisms management and adjuvant therapy.

Authors:  J G Docherty; J R McGregor; P J O'Dwyer; D J Galloway
Journal:  Br J Surg       Date:  1994-07       Impact factor: 6.939

6.  [Inhibitory effect of apatinib on HL-60 cell proliferation and its mechanism].

Authors:  Shu Liang; Xiu-zhen Tong; Li-wu Fu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2011-05

7.  A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.

Authors:  Pasquale Comella; Antonio Gambardella; Antonio Farris; Luigi Maiorino; Donato Natale; Bruno Massidda; Rossana Casaretti; Salvatore Tafuto; Vito Lorusso; Silvana Leo
Journal:  Crit Rev Oncol Hematol       Date:  2005-02       Impact factor: 6.312

8.  Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer.

Authors:  Shruti Setia; Bimla Nehru; Sankar Nath Sanyal
Journal:  Biomed Pharmacother       Date:  2014-09-29       Impact factor: 6.529

Review 9.  Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra.

Authors:  Isidro Ferrer; Anna María Planas
Journal:  J Neuropathol Exp Neurol       Date:  2003-04       Impact factor: 3.685

Review 10.  Apatinib for molecular targeted therapy in tumor.

Authors:  Haijun Zhang
Journal:  Drug Des Devel Ther       Date:  2015-11-13       Impact factor: 4.162

View more
  6 in total

Review 1.  Progress in the treatment of solid tumors with apatinib: a systematic review.

Authors:  Deze Zhao; Helei Hou; Xiaochun Zhang
Journal:  Onco Targets Ther       Date:  2018-07-19       Impact factor: 4.147

2.  Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling.

Authors:  Xiaomin Cai; Bin Wei; Lele Li; Xiaofeng Chen; Jing Yang; Xiaofei Li; Xiaozheng Jiang; Mu Lv; Mingyang Li; Yumeng Lin; Qiang Xu; Wenjie Guo; Yanhong Gu
Journal:  Onco Targets Ther       Date:  2020-10-29       Impact factor: 4.147

3.  Evaluation of the effect of ultrasound interventional injection of cisplatin in the treatment of liver cancer.

Authors:  Tao Zhang; Shengkai Cheng; Jianbo Li; Yangyang Shang; Mingyou Zheng
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Apatinib as an optional treatment in metastatic colorectal cancer.

Authors:  Aiyi Li; Kong Wang; Aiguo Xu; Gang Wang; Yongchang Miao; Zhichao Sun; Jingyu Zhang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  MKL1/miR-5100/CAAP1 loop regulates autophagy and apoptosis in gastric cancer cells.

Authors:  Hui-Min Zhang; Hui Li; Gen-Xin Wang; Jun Wang; Yuan Xiang; You Huang; Chao Shen; Zhou-Tong Dai; Jia-Peng Li; Tong-Cun Zhang; Xing-Hua Liao
Journal:  Neoplasia       Date:  2020-04-18       Impact factor: 5.715

6.  Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway.

Authors:  Hua Zhang; Yumei Cao; Yuru Chen; Guangxi Li; Hanshu Yu
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.